Home Members Paolo Andrea Zucali

Paolo Andrea Zucali

Associate Professor

Oncology

Director of the Residency School of Medical Oncology, Humanitas University; Head of the Genitourinary Oncology and rare tumors of the chest, Medical Oncology and Hematology Unit, Humanitas Cancer Center, Humanitas Research Hospital

E-mail

paolo.zucali@hunimed.eu

Paolo Andrea Zucali graduated at the Medical School of the University of Milan (Italy) in 1997. His post-graduate education continued with a Medical Oncology degree, achieved in 2002. He worked at the Division of Internal Medicine, IRCCS Policlinico Universitario in Milan and at the Division of Senology, IRCCS European Institute of Oncology in Milan, as clinical and research fellow. From April 2006 to October 2006 he was resident in Medical Oncology at the Department of Clinical Oncology of the VU Medisch Centrum in Amsterdam (The Netherlands). Since 2002 he is working at Humanitas Cancer Center, Humanitas Research Hospital – IRCCS, in Milan. From 2010 Head of Clinical Pharmacolgy Unit. He is Head of tumors of the genito-urinary tract and rare tumors of the chest (thymic epithelial tumors and pleural tumors). From November 2008 to October 2016 he was Adjunct Teaching Professor at the Medical School of the University of Milan. From November 2016 to June 2020 he was Adjunct Teaching Professor of Humanitas University. From July 2020 he is Since July 2020 he is Associate Professor of Medical Oncology at Humanitas University.

He is a member of the Italian Association of Medical Oncology (AIOM). He is a Member of the (EORTC) Group of thoracic tumors and Group of uro-oncologic tumors.

He is a founding partner and member of the steering committee of TYME, italian clinical and research network on thymic epithelial tumors (https://www.tyme.eu/), member of the AIOM Guidelines Writing Committee on Testis tumors, member of the Directive Committee of the MEET-URO Italian Network, and present member of the Directive Committee AIOM (Regional – Lombardia).

He is author of more than 100 articles published in peer-reviewed journals on the development of new treatments and biomarkers for genito-urinary tract and rare tumors of the chest (thymic epithelial tumors and pleural tumors). He is ad-hoc reviewer for several international scientific journals. He is speaker, chair, discussant, member of the organizing and scientific committee at national and international congresses and conferences

He has a long-standing interest in the field of clinical and translational cancer research, and he has been involved in more than 100 clinical trials (phase 1-2-3). From 2010, he focused his interest on patients with lung, thymomas, pleural and genito-urinary tract tumors treated with new drugs in national and international clinical and translational trials. Moreover, he also followed the development of new drugs in phase I trials. From 2012, he is Principal Investigator (PI) for national and international, multicenter, phase I/II/III clinical and translational trials of new drugs (small molecules, monoclonal antibodies, chemotherapy, immuno-oncology drugs) in solid tumors, in particular tumors of the genito-urinary tract and rare tumors of the chest (thymic epithelial tumors and pleural tumors).

Gregorc V*, Zucali PA*, Santoro A, Ceresoli GL, Citterio G, De Pas TM, Zilembo N, De Vincenzo F, Simonelli M, Rossoni G, Spreafico A, Grazia Viganò M, Fontana F, De Braud FG, Bajetta E, Caligaris-Cappio F, Bruzzi P, Lambiase A, Bordignon C. Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma. J Clin Oncol. 2010 May 20;28(15):2604-11. doi: 10.1200/JCO.2009.27.3649. *Equal contribution.
Zucali PA, Giovannetti E, Destro A, Mencoboni M, Ceresoli GL, Gianoncelli L, Lorenzi E, De Vincenzo F, Simonelli M, Perrino M, Bruzzone A, Thunnissen E, Tunesi G, Giordano L, Roncalli M, Peters GJ, Santoro A. Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin. Clin Cancer Res. 2011 Apr 15;17(8):2581-90. doi: 10.1158/1078-0432.CCR-10-2873.
Zucali PA, Simonelli M, De Vincenzo F, Lorenzi E, Perrino M, Bertossi M, Finotto R, Naimo S, Balzarini L, Bonifacio C, Timofeeva I, Rossoni G, Mazzola G, Lambiase A, Bordignon C, Santoro A. Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with refractory solid tumours. Br J Cancer. 2013 Jan 15;108(1):58-63. doi: 10.1038/bjc.2012.506.
Zucali PA, De Pas T, Palmieri G, Favaretto A, Chella A, Tiseo M, Caruso M, Simonelli M, Perrino M, De Vincenzo F, Toffalorio F, Damiano V, Pasello G, Garbella E, Ali M, Conforti F, Ottaviano M, Cioffi A, De Placido S, Giordano L, Bertossi M, Destro A, Di Tommaso L, Santoro A. Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy. J Clin Oncol. 2018 Feb 1;36(4):342-349. doi: 10.1200/JCO.2017.74.4078.
Zucali PA, Perrino M, De Vincenzo F, Giordano L, Cordua N, D’Antonio F, Santoro A. A phase II study of the combination of gemcitabine and imatinib mesylate in pemetrexed-pretreated patients with malignant pleural mesothelioma. Lung Cancer. 2020 Feb 12. pii: S0169-5002(20)30301-9. doi: 10.1016/j.lungcan.2020.02.005.